Headlines about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have been trending somewhat positive on Friday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.4265515019937 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Maxim Group Analysts Give Zynerba Pharmaceuticals (ZYNE) a $32.00 Price Target (americanbankingnews.com)
- Global Osteoarthritis Pain Drugs Market Research Findings, Market Growth Factors Analysis, Trends and Forecasts 2023 (journalhealthcare.com)
- Earnings per share (EPS) under Review – Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) (stocksmarketcap.com)
- Hot Stock’s Alert – Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) (stockspen.com)
- BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors (in.reuters.com)
ZYNE has been the topic of a number of research reports. Oppenheimer restated a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Wednesday, January 3rd. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, February 1st. Cantor Fitzgerald set a $20.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, March 12th. Seaport Global Securities started coverage on Zynerba Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Ladenburg Thalmann started coverage on Zynerba Pharmaceuticals in a report on Monday, January 29th. They set a “buy” rating and a $25.50 target price on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $17.86.
Shares of Zynerba Pharmaceuticals stock traded up $0.25 during trading hours on Friday, reaching $10.56. 201,688 shares of the company’s stock were exchanged, compared to its average volume of 322,959. Zynerba Pharmaceuticals has a 52-week low of $5.42 and a 52-week high of $24.57. The firm has a market cap of $135.07, a PE ratio of -4.14 and a beta of 4.94.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Monday, March 12th. The company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). During the same period in the previous year, the business earned ($0.71) earnings per share. analysts forecast that Zynerba Pharmaceuticals will post -2.63 EPS for the current fiscal year.
In other news, major shareholder Michael Rapp bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 22nd. The shares were acquired at an average cost of $9.28 per share, with a total value of $92,800.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 9.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock Price” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/20/zynerba-pharmaceuticals-zyne-given-daily-news-impact-rating-of-0-10.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.